FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281716842> ?p ?o ?g. }

• W4281716842 abstract "Neurofibromatosis type 1 (NF1) is an autosomal dominant multiorgan syndrome with an estimated global prevalence of 1/4000 involving aberrations of the NF1 gene on chromosome 17. Since the NF1 gene encodes a tumor suppressor protein called “neurofibromin” that downregulates Rat Sarcoma (RAS) activity, NF1 is associated with increased mortality and a variety of peripheral nerve sheath tumors. In particular plexiform neurofibromas (PNs) tend to appear during childhood.1 Selumetinib is a second-generation Adenosine TriPhosphate (ATP)-dependent mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor reported to induce a ≥ 20% size-reduction of inoperable PNs in children and adolescents.2 We hereby report a case of cutaneous side effects in a child treated with selumetinib for inoperable PNs, with a focus on its clinical management. A 14-year-old patient affected by a severe spinal form of NF-1 caused by a de novo heterozygous deletion of exons 9-10-11-12 on chromosome 17q11.2, was treated with a compassionate use protocol of selumetinib for massive inoperable PNs localized at the left shoulder girdle involving the ipsilateral brachial plexus and causing functional impairment with chronic pain. Treatment with selumetinib was started at the recommended dose of 25 mg/m2 twice a day. Five days after the introduction of the drug, he developed an extensive acneiform rash, characterized by erythematous papular and pustular lesions with a follicular disposition involving the face and upper part of the trunk (Figure 1A,B). A diagnosis of iatrogenic MEK1/2 inhibitor-induced acneiform rash was made. Firstly, the patient was treated with topical erythromycin cream and fusidic acid plus betamethasone cream with a slight worsening of the skin lesions. Systemic therapy with doxycycline (200 mg/day for 15 days) was then successfully administrated and the patient reached complete persistent clinical remission without scarring (Figure 1C,D). Based on the mild severity of the symptoms, treatment with selumetinib was continued at unchanged doses. Currently, the patient is still on treatment with selumetinib without any other episode of cutaneous lesions, with reduction of PNs mass and pain. In particular, the reduction in size of the PNs was minimal but the decrease of painful symptoms was very marked. Finally, it is worth noting that the PNs have been stable for about 12 months with no sign of a new volumetric increase. MEK inhibitors are emerging targeting agents that have already gained a crescent role in adult oncology. In the pediatric population, selumetinib is a recently approved innovative and effective treatment for inoperable PNs.2 Cutaneous manifestations, mainly in the form of acneiform skin rashes, have been reported in over 90% of patients,3 along with other side effects such as mild to moderate gastrointestinal symptoms (diarrhea, nausea, and vomiting), fatigue, and edema.4 Up to now, however, only few descriptions of dermatological toxicities in the pediatric population have been published5, 6 as well as the evidence regarding treatment and management strategies.7 Our patient showed a rash with erythematous follicular papulopustules, which appeared after few days of treatment with selumetinib and involved the face and upper trunk. The characteristic of this rash is analogous to those described in adults8: it tends to manifest as an acne-like rash within the first 2 weeks from the introduction of the drug and to be mild to moderate in degree, privileging the seborrheic areas such head and upper torso area.8 Consistently to our findings, in the current medical literature it has been reported that selumetinib-induced cutaneous rashes tend to assume different features in relation to the patient's age: in particular, acneiform rash is described mainly in post pubertal subjects, whereas maculopapular morbilliform manifestations are typical of younger children.7 In conclusion, considering the crucial role of selumetinib in reducing PNs development, it is presumable that it could have a more widespread use in pediatric patients with NF1 in the near future. It is important to highlight that the most common cutaneous effects can be promptly recognized and easily treated, thus not affecting the continuation of treatment nor limiting the dosage, even in children. All authors have contributed to the conception and the design of the study. All authors have contributed to the manuscript revision and they all have read and approved the submitted version. Open Access Funding provided by Universita degli Studi di Pavia within the CRUI-CARE Agreement. The authors declare no conflict of interest. Patient and parents have given their written informed consent to the publication of their case details. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions." @default.
• W4281716842 created "2022-06-13" @default.
• W4281716842 creator A5007520597 @default.
• W4281716842 creator A5012847262 @default.
• W4281716842 creator A5017558927 @default.
• W4281716842 creator A5032833406 @default.
• W4281716842 creator A5032870685 @default.
• W4281716842 creator A5039357425 @default.
• W4281716842 creator A5048731165 @default.
• W4281716842 creator A5063484453 @default.
• W4281716842 creator A5088990569 @default.
• W4281716842 date "2022-06-09" @default.
• W4281716842 modified "2023-10-18" @default.
• W4281716842 title "Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: Good results with doxycycline" @default.
• W4281716842 cites W2081267461 @default.
• W4281716842 cites W2129400742 @default.
• W4281716842 cites W2134758896 @default.
• W4281716842 cites W3010907970 @default.
• W4281716842 cites W3035332180 @default.
• W4281716842 cites W3047234385 @default.
• W4281716842 cites W3116437020 @default.
• W4281716842 cites W3128580436 @default.
• W4281716842 doi "https://doi.org/10.1111/dth.15607" @default.
• W4281716842 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35638252" @default.
• W4281716842 hasPublicationYear "2022" @default.
• W4281716842 type Work @default.
• W4281716842 citedByCount "1" @default.
• W4281716842 countsByYear W42817168422023 @default.
• W4281716842 crossrefType "journal-article" @default.
• W4281716842 hasAuthorship W4281716842A5007520597 @default.
• W4281716842 hasAuthorship W4281716842A5012847262 @default.
• W4281716842 hasAuthorship W4281716842A5017558927 @default.
• W4281716842 hasAuthorship W4281716842A5032833406 @default.
• W4281716842 hasAuthorship W4281716842A5032870685 @default.
• W4281716842 hasAuthorship W4281716842A5039357425 @default.
• W4281716842 hasAuthorship W4281716842A5048731165 @default.
• W4281716842 hasAuthorship W4281716842A5063484453 @default.
• W4281716842 hasAuthorship W4281716842A5088990569 @default.
• W4281716842 hasBestOaLocation W42817168421 @default.
• W4281716842 hasConcept C121608353 @default.
• W4281716842 hasConcept C126322002 @default.
• W4281716842 hasConcept C141071460 @default.
• W4281716842 hasConcept C142724271 @default.
• W4281716842 hasConcept C16005928 @default.
• W4281716842 hasConcept C170932241 @default.
• W4281716842 hasConcept C184235292 @default.
• W4281716842 hasConcept C2776087337 @default.
• W4281716842 hasConcept C2777831590 @default.
• W4281716842 hasConcept C2778173781 @default.
• W4281716842 hasConcept C2778472372 @default.
• W4281716842 hasConcept C2778570526 @default.
• W4281716842 hasConcept C2778984943 @default.
• W4281716842 hasConcept C2781187634 @default.
• W4281716842 hasConcept C526805850 @default.
• W4281716842 hasConcept C57074206 @default.
• W4281716842 hasConcept C71924100 @default.
• W4281716842 hasConcept C86803240 @default.
• W4281716842 hasConcept C95444343 @default.
• W4281716842 hasConceptScore W4281716842C121608353 @default.
• W4281716842 hasConceptScore W4281716842C126322002 @default.
• W4281716842 hasConceptScore W4281716842C141071460 @default.
• W4281716842 hasConceptScore W4281716842C142724271 @default.
• W4281716842 hasConceptScore W4281716842C16005928 @default.
• W4281716842 hasConceptScore W4281716842C170932241 @default.
• W4281716842 hasConceptScore W4281716842C184235292 @default.
• W4281716842 hasConceptScore W4281716842C2776087337 @default.
• W4281716842 hasConceptScore W4281716842C2777831590 @default.
• W4281716842 hasConceptScore W4281716842C2778173781 @default.
• W4281716842 hasConceptScore W4281716842C2778472372 @default.
• W4281716842 hasConceptScore W4281716842C2778570526 @default.
• W4281716842 hasConceptScore W4281716842C2778984943 @default.
• W4281716842 hasConceptScore W4281716842C2781187634 @default.
• W4281716842 hasConceptScore W4281716842C526805850 @default.
• W4281716842 hasConceptScore W4281716842C57074206 @default.
• W4281716842 hasConceptScore W4281716842C71924100 @default.
• W4281716842 hasConceptScore W4281716842C86803240 @default.
• W4281716842 hasConceptScore W4281716842C95444343 @default.
• W4281716842 hasIssue "8" @default.
• W4281716842 hasLocation W42817168421 @default.
• W4281716842 hasLocation W42817168422 @default.
• W4281716842 hasLocation W42817168423 @default.
• W4281716842 hasOpenAccess W4281716842 @default.
• W4281716842 hasPrimaryLocation W42817168421 @default.
• W4281716842 hasRelatedWork W1976009942 @default.
• W4281716842 hasRelatedWork W2006684864 @default.
• W4281716842 hasRelatedWork W2018563857 @default.
• W4281716842 hasRelatedWork W2276090771 @default.
• W4281716842 hasRelatedWork W2889507717 @default.
• W4281716842 hasRelatedWork W3031040949 @default.
• W4281716842 hasRelatedWork W3209698217 @default.
• W4281716842 hasRelatedWork W4283739039 @default.
• W4281716842 hasRelatedWork W4310471133 @default.
• W4281716842 hasRelatedWork W3133867946 @default.
• W4281716842 hasVolume "35" @default.
• W4281716842 isParatext "false" @default.
• W4281716842 isRetracted "false" @default.
• W4281716842 workType "article" @default.